Lentiviruses are a subgroup of retroviruses, characterized by their ability to cause a slow and progressive infection. The term "lenti" is derived from the Latin word "lentus," meaning slow, emphasizing the prolonged incubation period of these viruses. Human immunodeficiency virus (HIV), responsible for acquired immunodeficiency syndrome (AIDS), is the most well-known lentivirus. Lentiviruses have a single-stranded RNA genome that is reverse transcribed into DNA upon entering host cells, integrating into the host genome for persistent infection. Lentiviruses exhibit a broad host range, infecting various species, including humans and other mammals. Their ability to infect both dividing and non-dividing cells distinguishes lentiviruses from other retroviruses. Research on lentiviruses has led to significant insights into viral replication, host interactions, and the development of gene therapy vectors. Lentiviral vectors are used in biotechnology and gene therapy applications due to their ability to efficiently deliver genetic material into target cells.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States